CML Advocates Network

Absence of cells with the Philadelphia Chromosome in the bone marrow, usually detected by cytogenetics or FISH diagnostics

The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.

Tumours of the gastrointestinal tract which is commonly defined as the stomach and the intestine.

also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.

The first treatment given after a disease has been diagnosed. Patients who do not respond to or do not tolerate this treatment, will receive second-line therapy.

Also called induction therapy or primary treatment.

A phase of development of Chronic Myeloid Leukemia between chronic and blast phase. Untreated, the accelerated phase progresses to blast phase within a few months.

The earliest phase of CML development.

Proportion of patients (in percent) in whom a specific therapy led to a decrease in or disappearance of signs and symptoms of a disease.

An undesired or unintended occurrence or side effect that has a temporal relationship with the use of a medical treatment or procedure in a clinical study. An adverse event does not necessarily have a causal relationship with the study treatment.

Also called: AE

A medical product that is comparable to a brand/reference listed medical product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent protection and market exclusivity ends

The third phase of development of CML after chronic and accelerated phases. It is characterized by the presence of increasing numbers of immature blood cells ("blasts") in the blood and bone marrow.

A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)

Chemotherapy is the use of drugs to treat cancer by destroying or slowing the growth of fast-growing cancer cells. The term chemotherapy also includes treatment with antibiotics.

The science of the interactions between drugs and the body

Biosimilars also known as follow-on biologics are biologic medical products whose active drug substance is made by a living organism or derived from a living organism. Biosimilars or follow-on biologics are terms used to describe officially approved subsequent versions of biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the original product

Worsening of a cancer

Adverse effects of a treatment:, side effects limit the maximum tolerable dose in particular during chemotherapy.

The ability to withstand the effects of a drug, e.g. resistance of cancer cells to a specific therapy.

Name under which a drug is marketed by a specific manufacturer, which is different to the compound name which describes the active ingredient contained in a pharmaceutical product

A clinical trial in which researchers and participants know which treatment is being provided to each patient (opposite to "blinded trials" or "double-blind studies")

Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.

Uptake of a drug into the bloodstream

A medicine provided by third party manufacturers despite the medicine is still patented

Programmed cell death, triggered actively by the cell.

The condition of having a deficient number of one or more elements in the blood. Depending on which types of blood cells are decreased, the condition is also called leuko(cyto)penia, granulopenia, lympho(cyto)penia, mono(cyto)penia, erythro(cyto)penia or thrombo(cyto)penia.

A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.

The quality of being poisonous; harm resulting from drugs, e.g. side effects of chemotherapy.

Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec

The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22

Long-lasting, slowly developping

Condition where the bone marrow is defective and cannot form any blood cells

A sign of disease or disorder (Greek; accident, happening)

Lack of red blood cells or decrease in red blood pigment (haemoglobin)

An immature white blood cell that normally represents an early phase of the development process of a blood stem cell in the bone marrow

Abbreviation for Complete Cytogenetic Response, which is the absence of cells with the Philadelphia Chromosome in the bone marrow, usually detected by cytogenetics or FISH diagnostics

A unit of information present as DNA; a gene usually contains the blueprint for a protein.

Oral, pertaining to the mouth; taken through or applied in the mouth.

Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.

American Society of Hematology

Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.

ß-glucuronidase; an enzyme

Complementary and Alternative Medicine

Acute promyelocytic leukemia; a subtype of acute myelogenous leukemia (AML)

Absence of cells with the Philadelphia Chromosome in the bone marrow, usually detected by cytogenetics or FISH diagnostics

The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.

Tumours of the gastrointestinal tract which is commonly defined as the stomach and the intestine.

also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.

The first treatment given after a disease has been diagnosed. Patients who do not respond to or do not tolerate this treatment, will receive second-line therapy.

Also called induction therapy or primary treatment.

A phase of development of Chronic Myeloid Leukemia between chronic and blast phase. Untreated, the accelerated phase progresses to blast phase within a few months.

The earliest phase of CML development.

Proportion of patients (in percent) in whom a specific therapy led to a decrease in or disappearance of signs and symptoms of a disease.

An undesired or unintended occurrence or side effect that has a temporal relationship with the use of a medical treatment or procedure in a clinical study. An adverse event does not necessarily have a causal relationship with the study treatment.

Also called: AE

A medical product that is comparable to a brand/reference listed medical product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent protection and market exclusivity ends

The third phase of development of CML after chronic and accelerated phases. It is characterized by the presence of increasing numbers of immature blood cells ("blasts") in the blood and bone marrow.

A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)

Chemotherapy is the use of drugs to treat cancer by destroying or slowing the growth of fast-growing cancer cells. The term chemotherapy also includes treatment with antibiotics.

The science of the interactions between drugs and the body

Biosimilars also known as follow-on biologics are biologic medical products whose active drug substance is made by a living organism or derived from a living organism. Biosimilars or follow-on biologics are terms used to describe officially approved subsequent versions of biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the original product

Worsening of a cancer

Adverse effects of a treatment:, side effects limit the maximum tolerable dose in particular during chemotherapy.

The ability to withstand the effects of a drug, e.g. resistance of cancer cells to a specific therapy.

Name under which a drug is marketed by a specific manufacturer, which is different to the compound name which describes the active ingredient contained in a pharmaceutical product

A clinical trial in which researchers and participants know which treatment is being provided to each patient (opposite to "blinded trials" or "double-blind studies")

Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.

Uptake of a drug into the bloodstream

A medicine provided by third party manufacturers despite the medicine is still patented

Programmed cell death, triggered actively by the cell.

The condition of having a deficient number of one or more elements in the blood. Depending on which types of blood cells are decreased, the condition is also called leuko(cyto)penia, granulopenia, lympho(cyto)penia, mono(cyto)penia, erythro(cyto)penia or thrombo(cyto)penia.

A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.

The quality of being poisonous; harm resulting from drugs, e.g. side effects of chemotherapy.

Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec

The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22

Long-lasting, slowly developping

Condition where the bone marrow is defective and cannot form any blood cells

A sign of disease or disorder (Greek; accident, happening)

Lack of red blood cells or decrease in red blood pigment (haemoglobin)

An immature white blood cell that normally represents an early phase of the development process of a blood stem cell in the bone marrow

Abbreviation for Complete Cytogenetic Response, which is the absence of cells with the Philadelphia Chromosome in the bone marrow, usually detected by cytogenetics or FISH diagnostics

A unit of information present as DNA; a gene usually contains the blueprint for a protein.

Oral, pertaining to the mouth; taken through or applied in the mouth.

Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.

American Society of Hematology

Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.

ß-glucuronidase; an enzyme

Complementary and Alternative Medicine

Acute promyelocytic leukemia; a subtype of acute myelogenous leukemia (AML)